

Dana P Goldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1676320/publications.pdf>

Version: 2024-02-01

291
papers

13,593
citations

30070

54
h-index

29157

104
g-index

308
all docs

308
docs citations

308
times ranked

13787
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of COVID-19 vaccine allocation strategies on vaccination refusal: a national survey. <i>Journal of Risk Research</i> , 2022, 25, 1047-1054.	2.6	7
2	The costs of developing treatments for Alzheimer's disease: A retrospective exploration. <i>Alzheimer's and Dementia</i> , 2022, 18, 469-477.	0.8	40
3	Complexity Bias in the Prevention of Iatrogenic Injury. <i>Mayo Clinic Proceedings</i> , 2022, 97, 221-224.	3.0	8
4	Improved survival for individuals with common chronic conditions in the Medicare population. <i>Health Economics (United Kingdom)</i> , 2021, 30, 80-91.	1.7	1
5	Predicting quantity and quality of life with the Future Elderly Model. <i>Health Economics (United Kingdom)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.7	7
6	Disentangling moral hazard and adverse selection in private health insurance. <i>Journal of Econometrics</i> , 2021, 222, 141-160.	6.5	13
7	Smaller Regional Brain Volumes Predict Posttraumatic Stress Disorder at 3 Months After Mild Traumatic Brain Injury. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 352-359.	1.5	8
8	Simulating the Fiscal Impact of Anti-Obesity Medications as an Obesity Reduction Strategy. <i>Inquiry (United States)</i> , 2021, 58, 004695802199051.	0.9	3
9	The future of the elderly population health status: Filling a knowledge gap. <i>Health Economics (United Kingdom)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.7	10
10	The economics of alternative payment models for pharmaceuticals. <i>European Journal of Health Economics</i> , 2021, 22, 559-569.	2.8	10
11	Looking Ahead to 2030: Survey of Evolving Needs in Pharmacy Education. <i>Pharmacy (Basel, Switzerland)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	8
12	Spending On Targeted Therapies Reduced Mortality In Patients With Advanced-Stage Breast Cancer. <i>Health Affairs</i> , 2021, 40, 763-771.	5.2	5
13	Disparate ageing: The role of education and socioeconomic gradients in future health and disability in an international context. <i>Health Economics (United Kingdom)</i> , 2021, 30, 3-10.	1.7	3
14	Tractography-Pathology Correlations in Traumatic Brain Injury: A TRACK-TBI Study. <i>Journal of Neurotrauma</i> , 2021, 38, 1620-1631.	3.4	9
15	Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study. <i>JAMA Neurology</i> , 2021, 78, 982.	9.0	103
16	Comparing the Quality of Life after Brain Injury-Overall Scale and Satisfaction with Life Scale as Outcome Measures for Traumatic Brain Injury Research. <i>Journal of Neurotrauma</i> , 2021, 38, 3352-3363.	3.4	3
17	Gender differences in countries' adaptation to societal ageing: an international cross-sectional comparison. <i>The Lancet Healthy Longevity</i> , 2021, 2, e460-e469.	4.6	11
18	Opioid-related deaths before and after COVID-19 stay-at-home orders in Los Angeles County. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109028.	3.2	13

#	ARTICLE	IF	CITATIONS
19	Modelling the value of innovative treatments for Alzheimer's disease in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 764-769.	2.1	9
20	Trends in Racial and Ethnic Disparities in Diabetes-Related Complications, 1997-2017. <i>Journal of General Internal Medicine</i> , 2020, 35, 950-951.	2.6	8
21	Extended-Release Formulation and Medication Adherence. <i>Journal of General Internal Medicine</i> , 2020, 35, 354-356.	2.6	6
22	Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States. <i>JAMA Ophthalmology</i> , 2020, 138, 40.	2.5	31
23	Association Between Spending and Outcomes for Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 323-331.	1.6	7
24	Temporal Trends in Mortality after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Regression Analysis. <i>Structural Heart</i> , 2020, 4, 16-23.	0.6	4
25	Risk factors and costs associated with 30-day readmissions following alcohol-related hospitalizations in the United States from 2010 to 2015. <i>Alcohol</i> , 2020, 89, 19-25.	1.7	4
26	Lifetime Burden of Adult Congenital Heart Disease in the USA Using a Microsimulation Model. <i>Pediatric Cardiology</i> , 2020, 41, 1515-1525.	1.3	9
27	Point-of-Care Platform Blood Biomarker Testing of Glial Fibrillary Acidic Protein versus S100 Calcium-Binding Protein B for Prediction of Traumatic Brain Injuries: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study. <i>Journal of Neurotrauma</i> , 2020, 37, 2460-2467.	3.4	72
28	Political polarization in US residents' COVID-19 risk perceptions, policy preferences, and protective behaviors. <i>Journal of Risk and Uncertainty</i> , 2020, 61, 177-194.	1.5	164
29	Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?. <i>Journal of Policy Analysis and Management</i> , 2020, 39, 577-604.	1.4	23
30	The Societal Value of Broader Access to Antiobesity Medications. <i>Obesity</i> , 2020, 28, 429-436.	3.0	13
31	Associations of Intensive Lifestyle Intervention in Type 2 Diabetes With Health Care Use, Spending, and Disability. <i>JAMA Network Open</i> , 2020, 3, e2025488.	5.9	7
32	The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers. <i>MDM Policy and Practice</i> , 2019, 4, 238146831985538.	0.9	8
33	Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017. <i>Value in Health</i> , 2019, 22, 1387-1395.	0.3	8
34	Geographic variation in the delivery of high-value inpatient care. <i>PLoS ONE</i> , 2019, 14, e0213647.	2.5	4
35	Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study. <i>Lancet Neurology</i> , The, 2019, 18, 953-961.	10.2	150
36	Association Between State Medicaid Eligibility Thresholds and Deaths Due to Substance Use Disorders. <i>JAMA Network Open</i> , 2019, 2, e193056.	5.9	10

#	ARTICLE	IF	CITATIONS
37	The Affordable Care Act and Health Insurance Coverage Among People With Diagnosed and Undiagnosed Diabetes: Data From the National Health and Nutrition Examination Survey. <i>Diabetes Care</i> , 2019, 42, e179-e180.	8.6	11
38	Measuring The Lifetime Costs Of Serious Mental Illness And The Mitigating Effects Of Educational Attainment. <i>Health Affairs</i> , 2019, 38, 652-659.	5.2	37
39	Functional Status Examination versus Glasgow Outcome Scale Extended as Outcome Measures in Traumatic Brain Injuries: How Do They Compare?. <i>Journal of Neurotrauma</i> , 2019, 36, 2423-2429.	3.4	14
40	Short-term budget affordability of hepatitis C treatments for state Medicaid programs. <i>BMC Health Services Research</i> , 2019, 19, 140.	2.2	16
41	Racial and ethnic disparities in medication adherence among privately insured patients in the United States. <i>PLoS ONE</i> , 2019, 14, e0212117.	2.5	79
42	The long-term impact of functional disability on hospitalization spending in Singapore. <i>Journal of the Economics of Ageing</i> , 2019, 14, 100193.	1.3	25
43	Higher Surgeon Procedure Volume is Associated with Improved Hemodialysis Vascular Access Outcomes. <i>American Surgeon</i> , 2019, 85, 1079-1082.	0.8	6
44	Who Pays in Medicare Part D? Giving Plans More Skin in the Game. <i>New England Journal of Medicine</i> , 2019, 381, 2384-2387.	27.0	4
45	Valuing innovations in cancer treatment.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18176-e18176.	1.6	0
46	347-OR: The Long-Term Effects of an Intensive Lifestyle Intervention on Medicare Outcomes. <i>Diabetes</i> , 2019, 68, 347-OR.	0.6	0
47	Higher Surgeon Procedure Volume Is Associated with Improved Hemodialysis Vascular Access Outcomes. <i>American Surgeon</i> , 2019, 85, 1079-1082.	0.8	3
48	The potential impact of CAR T-cell treatment delays on society. <i>American Journal of Managed Care</i> , 2019, 25, 379-386.	1.1	8
49	The long-term social value of granulocyte colony-stimulating factors. <i>American Journal of Managed Care</i> , 2019, 25, 486-493.	1.1	3
50	Acute Myocardial Infarction Mortality During Dates of National Interventional Cardiology Meetings. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	17
51	Accelerating Alzheimer's disease drug innovations from the research pipeline to patients. <i>Alzheimer's and Dementia</i> , 2018, 14, 833-836.	0.8	25
52	Long-Term Health and Economic Value of Improved Mobility among Older Adults in the United States. <i>Value in Health</i> , 2018, 21, 792-798.	0.3	16
53	Do Physicians Respond to the Costs and Cost-Sensitivity of Their Patients?. <i>American Economic Journal: Economic Policy</i> , 2018, 10, 113-152.	3.1	20
54	Measuring how countries adapt to societal aging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 435-437.	7.1	21

#	ARTICLE	IF	CITATIONS
55	IT IS TIME FOR UNIVERSAL COVERAGE WITHOUT BREAKING THE BANK. <i>Journal of Policy Analysis and Management</i> , 2018, 37, 182-188.	1.4	1
56	MEDICAREâ€œFORâ€œALL: NOT OUR ONLY OPTION FOR UNIVERSAL COVERAGE. <i>Journal of Policy Analysis and Management</i> , 2018, 37, 195-198.	1.4	0
57	Productivity Benefits of Medical Care: Evidence from US-Based Randomized Clinical Trials. <i>Value in Health</i> , 2018, 21, 905-910.	0.3	3
58	Innovation in Heart Failure Treatment. <i>JACC: Heart Failure</i> , 2018, 6, 401-409.	4.1	34
59	Frequency and Magnitude of Co-payments Exceeding Prescription Drug Costs. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1045.	7.4	14
60	Development of a Group Judgment Process for Forecasts of Health Care Innovations. <i>JAMA Network Open</i> , 2018, 1, e185108.	5.9	4
61	Measuring Sarcopenia Severity in Older Adults and the Value of Effective Interventions. <i>Journal of Nutrition, Health and Aging</i> , 2018, 22, 1253-1258.	3.3	5
62	Assessment of Follow-up Care After Emergency Department Presentation for Mild Traumatic Brain Injury and Concussion. <i>JAMA Network Open</i> , 2018, 1, e180210.	5.9	119
63	Estimated prevalence of undiagnosed atrial fibrillation in the United States. <i>PLoS ONE</i> , 2018, 13, e0195088.	2.5	116
64	Insulin Access and Affordability Working Group: Conclusions and Recommendations. <i>Diabetes Care</i> , 2018, 41, 1299-1311.	8.6	210
65	Multidimensional comparison of countriesâ€™ adaptation to societal aging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 9169-9174.	7.1	37
66	The social value of tisagenlecleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States: What are consequences of treatment delays?. <i>Journal of Clinical Oncology</i> , 2018, 36, 10529-10529.	1.6	2
67	Variations in outcomes of hemodialysis vascular access by race/ethnicity in the elderly. <i>Journal of Vascular Surgery</i> , 2017, 65, 783-792.e4.	1.1	14
68	Using Self-reports or Claims to Assess Disease Prevalence. <i>Medical Care</i> , 2017, 55, 782-788.	2.4	33
69	Raising the Social Security Entitlement Age. <i>Research on Aging</i> , 2017, 39, 166-189.	1.8	3
70	PCSK9 Inhibitors Show Value for Patients and the US Health Care System. <i>Value in Health</i> , 2017, 20, 1270-1278.	0.3	7
71	Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals. <i>Annals of Internal Medicine</i> , 2017, 166, 219.	3.9	10
72	Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors. <i>JAMA Cardiology</i> , 2017, 2, 1063.	6.1	3

#	ARTICLE	IF	CITATIONS
73	Encouraging New Uses for Old Drugs. JAMA - Journal of the American Medical Association, 2017, 318, 2421.	7.4	29
74	Projecting diabetes prevalence among Mexicans aged 50 years and older: the Future Elderly Model-Mexico (FEM-Mexico). BMJ Open, 2017, 7, e017330.	1.9	22
75	How the Growing Gap in Life Expectancy May Affect Retirement Benefits and Reforms. Geneva Papers on Risk and Insurance: Issues and Practice, 2017, 42, 475-499.	2.1	37
76	The association between observed mobility and quality of life in the near elderly. PLoS ONE, 2017, 12, e0182920.	2.5	44
77	Society and the Individual at the Dawn of the Twenty-First Century. , 2016, , 41-62.		1
78	Authors' reply to Bosco-LÃ©vy and Salvo. BMJ, The, 2016, 354, i4330.	6.0	0
79	Competing Risks. American Journal of Preventive Medicine, 2016, 50, S45-S50.	3.0	5
80	Health Care Spending: Historical Trends and New Directions. Annual Review of Economics, 2016, 8, 291-319.	5.5	22
81	Hospital Prescribing of Opioids to Medicare Beneficiaries. JAMA Internal Medicine, 2016, 176, 990.	5.1	71
82	The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV. Medical Care Research and Review, 2016, 73, 329-348.	2.1	4
83	Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection. Forum for Health Economics and Policy, 2016, 19, 141-156.	0.8	5
84	Are Biopharmaceutical Budget Caps Good Public Policy?. Economists' Voice, 2016, 13, 27-42.	0.2	0
85	The Economic Promise of Delayed Aging. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a025072.	6.2	18
86	The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. PLoS ONE, 2016, 11, e0166103.	2.5	8
87	Impact of type 2 diabetes medication cost sharing on patient outcomes and health plan costs. American Journal of Managed Care, 2016, 22, 433-40.	1.1	20
88	Value of improved lipid control in patients at high risk for adverse cardiac events. American Journal of Managed Care, 2016, 22, e199-207.	1.1	14
89	Health and Health Care of Medicare Beneficiaries in 2030. Forum for Health Economics and Policy, 2015, 18, 75-96.	0.8	39
90	The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization. Health Services Research, 2015, 50, 883-896.	2.0	7

#	ARTICLE	IF	CITATIONS
91	Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 203-213.	1.4	2
92	Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. <i>BMJ, The</i> , 2015, 351, h6223.	6.0	30
93	Mortality and Treatment Patterns Among Patients Hospitalized With Acute Cardiovascular Conditions During Dates of National Cardiology Meetings. <i>JAMA Internal Medicine</i> , 2015, 175, 237.	5.1	56
94	Do Statins Reduce the Health and Health Care Costs of Obesity?. <i>Pharmacoeconomics</i> , 2015, 33, 723-734.	3.3	16
95	US Hospitals Experienced Substantial Productivity Growth During 2002â€“11. <i>Health Affairs</i> , 2015, 34, 511-518.	5.2	16
96	Hospital Productivity: The Authors Reply. <i>Health Affairs</i> , 2015, 34, 1069-1069.	5.2	0
97	Resetting Social Security. <i>Daedalus</i> , 2015, 144, 68-79.	1.8	7
98	Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States. <i>American Journal of Cardiology</i> , 2015, 116, 733-739.	1.6	73
99	Individual & Social Strategies to Mitigate the Risks & Expand Opportunities of an Aging America. <i>Daedalus</i> , 2015, 144, 93-102.	1.8	4
100	Incidence of Sexually Transmitted Infections After Human Papillomavirus Vaccination Among Adolescent Females. <i>JAMA Internal Medicine</i> , 2015, 175, 617.	5.1	63
101	Aligning incentives to fulfil the promise of personalised medicine. <i>Lancet, The</i> , 2015, 385, 2118-2119.	13.7	72
102	Cancer Mortality Reductions Were Greatest Among Countries Where Cancer Care Spending Rose The Most, 1995â€“2007. <i>Health Affairs</i> , 2015, 34, 562-570.	5.2	22
103	Robot-Assisted Surgery For Kidney Cancer Increased Access To A Procedure That Can Reduce Mortality And Renal Failure. <i>Health Affairs</i> , 2015, 34, 220-228.	5.2	14
104	Early Failure of Dialysis Access among the Elderly in the Era of Fistula First. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1791-1798.	4.5	53
105	Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Nonâ€“Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 196.	7.1	19
106	Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. <i>Health Affairs</i> , 2015, 34, 1666-1674.	5.2	30
107	The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma. <i>JAMA Internal Medicine</i> , 2015, 175, 1171.	5.1	22
108	Did Medicare Part D reduce disparities?. <i>American Journal of Managed Care</i> , 2015, 21, 119-28.	1.1	15

#	ARTICLE	IF	CITATIONS
109	Medication adherence and measures of health plan quality. American Journal of Managed Care, 2015, 21, e379-89.	1.1	13
110	Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants. Forum for Health Economics and Policy, 2014, 17, 153-168.	0.8	4
111	HIV Care Providers Emphasize The Importance Of The Ryan White Program For Access To And Quality Of Care. Health Affairs, 2014, 33, 394-400.	5.2	27
112	The Association between Employee Obesity and Employer Costs: Evidence from a Panel of U.S. Employers. American Journal of Health Promotion, 2014, 28, 277-285.	1.7	45
113	The Prospect Of A Generation Free Of HIV May Be Within Reach If The Right Policy Decisions Are Made. Health Affairs, 2014, 33, 428-433.	5.2	10
114	Identifying Patients at Risk for High Medical Costs and Good Candidates for Obesity Intervention. American Journal of Health Promotion, 2014, 28, 218-227.	1.7	6
115	Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims. BMJ, The, 2014, 348, g1393-g1393.	6.0	116
116	The Growing Gap in Life Expectancy: Using the Future Elderly Model to Estimate Implications for Social Security and Medicare. American Economic Review, 2014, 104, 230-233.	8.5	26
117	Preparedness of Americans for the Affordable Care Act. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5497-5502.	7.1	46
118	Data-Driven Decision-Making Tools To Improve Public Resource Allocation For Care And Prevention Of HIV/AIDS. Health Affairs, 2014, 33, 410-417.	5.2	10
119	RESPONSE TO EPSTEIN'S COMMENT ON "HETEROGENEITY IN ACTION" Health Economics (United Kingdom) 2014, 23, 359-373.	1.7	22
120	Hospital Costs and Inpatient Mortality among Children Undergoing Surgery for Congenital Heart Disease. Health Services Research, 2014, 49, 588-608.	2.0	25
121	HETEROGENEITY IN ACTION: THE ROLE OF PASSIVE PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH. Health Economics (United Kingdom), 2014, 23, 359-373.	1.7	22
122	Early HIV Treatment Led To Life Expectancy Gains Valued At \$80 Billion For People Infected In 1996-2009. Health Affairs, 2014, 33, 370-377.	5.2	32
123	Nearly 60,000 Uninsured And Low-Income People With HIV/AIDS Live In States That Are Not Expanding Medicaid. Health Affairs, 2014, 33, 386-393.	5.2	35
124	Specialty Drug Spending Trends Among Medicare And Medicare Advantage Enrollees, 2007-2011. Health Affairs, 2014, 33, 2018-2024.	5.2	21
125	The Future of US Health Care: Is Medicare Really Better at Saving Money?. Economists' Voice, 2014, 11, .	0.2	0
126	Early HIV Treatment In The United States Prevented Nearly 13,500 Infections Per Year During 1996-2009. Health Affairs, 2014, 33, 362-369.	5.2	22

#	ARTICLE	IF	CITATIONS
127	Heterogeneity in Healthy Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 640-649.	3.6	327
128	Five Myths About Cancer Care In America. Health Affairs, 2014, 33, 1801-1804.	5.2	8
129	Can the ACA Improve Population Health?. , 2014, , 30-38.		0
130	Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. American Journal of Managed Care, 2014, 20, e52-60.	1.1	19
131	Do strict formularies replicate failure for patients with schizophrenia?. American Journal of Managed Care, 2014, 20, 219-28.	1.1	2
132	Medicaid prior authorization policies and imprisonment among patients with schizophrenia. American Journal of Managed Care, 2014, 20, 577-86.	1.1	7
133	MEDICAL EXPENDITURE RISK AND HOUSEHOLD PORTFOLIO CHOICE. Journal of Applied Econometrics, 2013, 28, 527-550.	2.3	58
134	Confounding in the Association of Proton Pump Inhibitor Use With Risk of Community-Acquired Pneumonia. Journal of General Internal Medicine, 2013, 28, 223-230.	2.6	53
135	Community-Acquired Pneumonia and Proton Pump Inhibitors. Journal of General Internal Medicine, 2013, 28, 874-875.	2.6	0
136	Digesting the doughnut hole. Journal of Health Economics, 2013, 32, 1345-1355.	2.7	22
137	Introduction. Journal of Health Economics, 2013, 32, 1258-1262.	2.7	0
138	Health Care Costs And Clinical Outcomes Associated With Rates Of Sulfonylurea Use By Physicians. Value in Health, 2013, 16, A173-A174.	0.3	0
139	Substantial Health And Economic Returns From Delayed Aging May Warrant A New Focus For Medical Research. Health Affairs, 2013, 32, 1698-1705.	5.2	235
140	Three Large-Scale Changes To The Medicare Program Could Curb Its Costs But Also Reduce Enrollment. Health Affairs, 2013, 32, 891-899.	5.2	4
141	The Value of Diagnostic Testing in Personalized Medicine. Forum for Health Economics and Policy, 2013, 16, S87-S99.	0.8	13
142	Delayed Aging Versus Delayed Disease: A New Paradigm for Public Health. The Public Policy and Aging Report, 2013, 23, 16-18.	1.1	8
143	Want More Value from Prescription Drugs? We Need to Let Prices Rise and Fall. Economists' Voice, 2013, 10, 39-43.	0.2	1
144	Spending and mortality in US acute care hospitals. American Journal of Managed Care, 2013, 19, e46-54.	1.1	22

#	ARTICLE	IF	CITATIONS
145	Comparative effectiveness research and formulary placement: the case of diabetes. American Journal of Managed Care, 2013, 19, 93-6.	1.1	4
146	Impact of oral nutritional supplementation on hospital outcomes. American Journal of Managed Care, 2013, 19, 121-8.	1.1	115
147	Measuring the value of better diabetes management. American Journal of Managed Care, 2013, 19 Spec No. 2, E11.	1.1	2
148	Undiagnosed Disease, Especially Diabetes, Casts Doubt On Some Of Reported Health "Advantage" Of Recent Mexican Immigrants. Health Affairs, 2012, 31, 2727-2737.	5.2	71
149	Patients' Willingness To Pay: The Authors Reply. Health Affairs, 2012, 31, 1909-1909.	5.2	0
150	An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is "Worth It" In The Case Of Cancer. Health Affairs, 2012, 31, 667-675.	5.2	57
151	Survey Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs. Health Affairs, 2012, 31, 683-690.	5.2	20
152	An Economic Analysis of Conservative Management Versus Active Treatment for Men with Localized Prostate Cancer. Journal of the National Cancer Institute Monographs, 2012, 2012, 250-257.	2.1	18
153	Out-of-Pocket Medication Costs and Use of Medications and Health Care Services Among Children With Asthma. JAMA - Journal of the American Medical Association, 2012, 307, 1284.	7.4	96
154	A Reexamination of the Costs of Medical R&D Regulation. Forum for Health Economics and Policy, 2012, 15, 1-28.	0.8	3
155	The Large Social Value Resulting From Use Of Statins Warrants Steps To Improve Adherence And Broaden Treatment. Health Affairs, 2012, 31, 2276-2285.	5.2	43
156	Diabetes Management For Low-Income Patients In Los Angeles: Two Strategies Improved Disease Control In The Short Term. Health Affairs, 2012, 31, 168-176.	5.2	15
157	Patients Value Metastatic Cancer Therapy More Highly Than Is Typically Shown Through Traditional Estimates. Health Affairs, 2012, 31, 691-699.	5.2	31
158	Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Current Medical Research and Opinion, 2012, 28, 1959-1967.	1.9	23
159	Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population. Diabetes Technology and Therapeutics, 2012, 14, 904-911.	4.4	74
160	Differences In Life Expectancy Due To Race And Educational Differences Are Widening, And Many May Not Catch Up. Health Affairs, 2012, 31, 1803-1813.	5.2	522
161	The value of medical and pharmaceutical interventions for reducing obesity. Journal of Health Economics, 2012, 31, 630-643.	2.7	24
162	The Disability Burden of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 513-521.	1.6	49

#	ARTICLE	IF	CITATIONS
163	Consumer Demand and Health Effects of Cost-Sharing. , 2012, , .		0
164	Time to ADT and chemotherapy initiation for treatment of metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2012, 30, 41-41.	1.6	1
165	Treating people right: Who goes untreated with systemic therapy for metastatic prostate cancer (mPC)?. Journal of Clinical Oncology, 2012, 30, 125-125.	1.6	0
166	Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis. American Journal of Managed Care, 2012, 18, 460-4.	1.1	22
167	Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens. American Journal of Managed Care, 2012, 18, s191-202.	1.1	0
168	Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia. American Journal of Managed Care, 2012, 18, S272-8.	1.1	6
169	How Much Savings Can We Wring from Medicare?. New England Journal of Medicine, 2011, 365, e29.	27.0	10
170	Association Between the Birth of Twins and Parental Divorce. Obstetrics and Gynecology, 2011, 117, 892-897.	2.4	38
171	Prescription Medication Abuse and Illegitimate Internet-Based Pharmacies. Annals of Internal Medicine, 2011, 155, 848.	3.9	24
172	Patient Cost-Sharing and Healthcare Spending Growth. Journal of Economic Perspectives, 2011, 25, 47-68.	5.9	119
173	Hospital Spending and Inpatient Mortality: Evidence From California. Annals of Internal Medicine, 2011, 154, 160.	3.9	81
174	How Costly is Hospital Quality? A Revealedâ€Preference Approach. Journal of Industrial Economics, 2011, 59, 578-608.	1.3	36
175	Coverage and Preventive Screening. Health Services Research, 2011, 46, 173-184.	2.0	17
176	The increasing value of education to health. Social Science and Medicine, 2011, 72, 1728-1737.	3.8	110
177	Differences in health between Americans and Western Europeans: Effects on longevity and public finance. Social Science and Medicine, 2011, 73, 254-263.	3.8	39
178	Racial and ethnic disparities in hospital care resulting from air pollution in excess of federal standards. Social Science and Medicine, 2011, 73, 1163-1168.	3.8	27
179	Medicaid Cost Control Measures Aimed At Second-Generation Antipsychotics Led To Less Use Of All Antipsychotics. Health Affairs, 2011, 30, 2346-2354.	5.2	27
180	Growing Internet Use May Help Explain The Rise In Prescription Drug Abuse In The United States. Health Affairs, 2011, 30, 1192-1199.	5.2	31

#	ARTICLE	IF	CITATIONS
181	Market Exclusivity For Drugs: The Authors Reply. Health Affairs, 2011, 30, 799-799.	5.2	0
182	The Benefits From Giving Makers Of Conventional "Small Molecule"™ Drugs Longer Exclusivity Over Clinical Trial Data. Health Affairs, 2011, 30, 84-90.	5.2	29
183	Medical Expenditure Measures in the Health and Retirement Study. Forum for Health Economics and Policy, 2011, 14, 4.	0.8	18
184	Part D Formulary and Benefit Design as a Risk-Steering Mechanism. American Economic Review, 2011, 101, 382-386.	8.5	7
185	Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products. Handbook of Health Economics, 2011, 2, 825-872.	0.2	1
186	Physician prescribing behavior and its impact on patient-level outcomes. American Journal of Managed Care, 2011, 17, e462-71.	1.1	11
187	Criminal Prosecution and Human Immunodeficiency Virus-Related Risky Behavior. Journal of Law and Economics, 2010, 53, 741-782.	1.4	9
188	Prescription Drug Coverage and Medicare Spending among U.S. Elderly. Geneva Papers on Risk and Insurance: Issues and Practice, 2010, 35, 539-567.	2.1	2
189	The potential impact of comparative effectiveness research on U.S. Health Care expenditures. Demography, 2010, 47, S173-S190.	2.5	28
190	Can patient self-management explain the health gradient? Goldman and Smith (2002) revisited: A response to Maitra. Social Science and Medicine, 2010, 70, 813-815.	3.8	5
191	Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA. Health Economics (United Kingdom), 2010, 19, 1109-1116.	1.7	32
192	The Value of Specialty Oncology Drugs. Health Services Research, 2010, 45, 115-132.	2.0	49
193	Cost Sharing, Family Health Care Burden, and the Use of Specialty Drugs for Rheumatoid Arthritis. Health Services Research, 2010, 45, 1227-1250.	2.0	46
194	Geographic Variation in Health Care: The Role of Private Markets. Brookings Papers on Economic Activity, 2010, 2010, 325-355.	1.5	33
195	Sexually Transmitted Diseases Among Users of Erectile Dysfunction Drugs: Analysis of Claims Data. Annals of Internal Medicine, 2010, 153, 1.	3.9	65
196	The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000. Forum for Health Economics and Policy, 2010, 13, .	0.8	12
197	The Emerging Importance of Patient Amenities in Hospital Care. New England Journal of Medicine, 2010, 363, 2185-2187.	27.0	41
198	An economic evaluation of the war on cancer. Journal of Health Economics, 2010, 29, 333-346.	2.7	74

#	ARTICLE	IF	CITATIONS
199	THE FISCAL CONSEQUENCES OF TRENDS IN POPULATION HEALTH. National Tax Journal, 2010, 63, 307-330.	1.2	20
200	Bending the curve through health reform implementation. American Journal of Managed Care, 2010, 16, 804-12.	1.1	3
201	Cost Sharing and the Initiation of Drug Therapy for the Chronically Ill. Archives of Internal Medicine, 2009, 169, 740.	3.8	48
202	Clinical and Behavioral Correlates of Achieving and Maintaining Glycemic Targets in an Underserved Population With Type 2 Diabetes. Diabetes Care, 2009, 32, 54-56.	8.6	19
203	Ageing in America in the Twenty-first Century: Demographic Forecasts from the MacArthur Foundation Research Network on an Aging Society. Milbank Quarterly, 2009, 87, 842-862.	4.4	147
204	Market evidence of misperceived mortality risk. Journal of Economic Behavior and Organization, 2009, 72, 451-462.	2.0	11
205	The Benefits of Risk Factor Prevention in Americans Aged 51 Years and Older. American Journal of Public Health, 2009, 99, 2096-2101.	2.7	62
206	Toward a 21st-Century Health Care System: Recommendations for Health Care Reform. Annals of Internal Medicine, 2009, 150, 493.	3.9	68
207	Medicare part D after 2 years. American Journal of Managed Care, 2009, 15, 536-44.	1.1	12
208	Bending the curve: effective steps to address long-term healthcare spending growth. American Journal of Managed Care, 2009, 15, 676-80.	1.1	12
209	Does age or life expectancy better predict health care expenditures?. Health Economics (United Tj ETQq1 1 0.784314 rgBT /Qyerlock 1.7 67)	1.7	67
210	Drug costs and out-of-pocket spending in cancer clinical trials. Contemporary Clinical Trials, 2008, 29, 1-8.	1.8	11
211	The Effect Of Regulation On Pharmaceutical Revenues: Experience In Nineteen Countries. Health Affairs, 2008, 27, w125-w137.	5.2	64
212	U.S. Pharmaceutical Policy In A Global Marketplace. Health Affairs, 2008, 27, w138-w150.	5.2	39
213	Want to Monitor Medicare's New Drug Benefit Program? Start by Sending a Check for \$120,000. Economists' Voice, 2008, 5, .	0.2	0
214	Medicare Part D. JAMA - Journal of the American Medical Association, 2008, 299, 1954-5.	7.4	14
215	Drug Licenses: A New Model For Pharmaceutical Pricing. Health Affairs, 2008, 27, 122-129.	5.2	17
216	Impact of specialty drugs on the use of other medical services. American Journal of Managed Care, 2008, 14, 821-8.	1.1	12

#	ARTICLE	IF	CITATIONS
217	Prescription Drug Cost Sharing. JAMA - Journal of the American Medical Association, 2007, 298, 61.	7.4	741
218	Pharmacy Benefit Caps And The Chronically Ill. Health Affairs, 2007, 26, 1333-1344.	5.2	26
219	The Promise Of Health Care Cost Containment. Health Affairs, 2007, 26, 1545-1547.	5.2	17
220	Integrated Insurance Design in the Presence of Multiple Medical Technologies. American Economic Review, 2007, 97, 427-432.	8.5	53
221	Medical Expenditure Risk and Household Portfolio Choice. SSRN Electronic Journal, 2007, , .	0.4	4
222	Immigrants And The Cost Of Medical Care. Health Affairs, 2006, 25, 1700-1711.	5.2	109
223	Estimating probit models with self-selected treatments. Statistics in Medicine, 2006, 25, 389-413.	1.6	162
224	HIV Breakthroughs and Risky Sexual Behavior*. Quarterly Journal of Economics, 2006, 121, 1063-1102.	8.6	126
225	Rising Medicare Costs: Are We In Crisis?. Health Affairs, 2006, 25, W389-W390.	5.2	6
226	The Value of Elderly Disease Prevention. Forum for Health Economics and Policy, 2006, 9, .	0.8	17
227	Adverse Selection in Retiree Prescription Drug Plans. Forum for Health Economics and Policy, 2006, 9, .	0.8	3
228	Benefit Design And Specialty Drug Use. Health Affairs, 2006, 25, 1319-1331.	5.2	109
229	Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. American Journal of Managed Care, 2006, 12, 21-8.	1.1	90
230	Socioeconomic Differences in the Adoption of New Medical Technologies. American Economic Review, 2005, 95, 234-237.	8.5	29
231	A Socioeconomic Profile of Older Adults With HIV. Journal of Health Care for the Poor and Underserved, 2005, 16, 19-28.	0.8	19
232	Technological Advances In Cancer And Future Spending By The Elderly. Health Affairs, 2005, 24, W5-R53-W5-R66.	5.2	20
233	Consequences Of Health Trends And Medical Innovation For The Future Elderly. Health Affairs, 2005, 24, W5-R5-W5-R17.	5.2	126
234	The Health And Cost Consequences Of Obesity Among The Future Elderly. Health Affairs, 2005, 24, W5-R30-W5-R41.	5.2	124

#	ARTICLE	IF	CITATIONS
235	Identifying Potential Health Care Innovations For The Future Elderly. Health Affairs, 2005, 24, W5-R67-W5-R76.	5.2	21
236	The Lifetime Burden Of Chronic Disease Among The Elderly. Health Affairs, 2005, 24, W5-R18-W5-R29.	5.2	52
237	Legal Status And Health Insurance Among Immigrants. Health Affairs, 2005, 24, 1640-1653.	5.2	117
238	Disability And Health Care Spending Among Medicare Beneficiaries. Health Affairs, 2005, 24, W5-R42-W5-R52.	5.2	41
239	A Theory of Health Disparities and Medical Technology. BE Journal of Economic Analysis and Policy, 2005, 4, .	0.2	39
240	The reallocation of compensation in response to health insurance premium increases. Economics Letters, 2005, 88, 147-151.	1.9	2
241	Moving towards better formulary management. American Journal of Managed Care, 2005, 11, 13-4.	1.1	4
242	Pharmacy Benefits and the Use of Drugs by the Chronically Ill. JAMA - Journal of the American Medical Association, 2004, 291, 2344.	7.4	433
243	Are The Young Becoming More Disabled?. Health Affairs, 2004, 23, 168-176.	5.2	206
244	Disability Forecasts and Future Medicare Costs. Forum for Health Economics and Policy, 2004, 7, 75-94.	0.8	20
245	The Changing Face Of Pharmacy Benefit Design. Health Affairs, 2004, 23, 194-199.	5.2	52
246	Effective HIV Treatment and the Employment of HIV+ Adults. Health Services Research, 2004, 39, 1691-1712.	2.0	53
247	Price Regulation in Secondary Insurance Markets. Journal of Risk and Insurance, 2004, 71, 643-675.	1.6	12
248	Effect of an imaging-based streamlined electronic healthcare process on quality and costs1. Academic Radiology, 2004, 11, 13-20.	2.5	5
249	Increased Medicare Expenditures for Physicians' Services: What are the Causes?. Inquiry (United Tj ETQq1 1 0.784314 rgBT /Overlock 11	0.9	11
250	Health Status and Medical Treatment of the Future Elderly: Final Report. , 2004, , .		46
251	Employee responses to health insurance premium increases. American Journal of Managed Care, 2004, 10, 41-7.	1.1	11
252	An Analysis of Unobserved Selection in an Inpatient Diagnostic Cost Group Model. Health Services and Outcomes Research Methodology, 2003, 4, 71-91.	1.8	2

#	ARTICLE	IF	CITATIONS
253	Sampling Patients Within and Across Health Care Providers: Multi-Stage Non-Nested Samples in Health Services Research. <i>Health Services and Outcomes Research Methodology</i> , 2003, 4, 151-167.	1.8	2
254	The link between public and private insurance and HIV-related mortality. <i>Journal of Health Economics</i> , 2003, 22, 1105-1122.	2.7	103
255	High Out-Of-Pocket Health Care Spending By The Elderly. <i>Health Affairs</i> , 2003, 22, 194-202.	5.2	71
256	Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2003, 21, 1383-1389.	1.6	936
257	A Response to the Points by Manton and Williamson. <i>Medical Care</i> , 2003, 41, 28-31.	2.4	2
258	Forecasting the Nursing Home Population. <i>Medical Care</i> , 2003, 41, 8-20.	2.4	95
259	Incremental Treatment Costs in National Cancer Institute-sponsored Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2970.	7.4	70
260	Insurance status of HIV-infected adults in the post-HAART era: evidence from the United States. <i>Applied Health Economics and Health Policy</i> , 2003, 2, 85-90.	2.1	19
261	Employer Drug Benefit Plans and Spending on Prescription Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 1733.	7.4	168
262	The Costs of A Medicare Prescription Drug Benefit. <i>BE Journal of Economic Analysis and Policy</i> , 2002, 2, .	0.3	5
263	Can patient self-management help explain the SES health gradient?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10929-10934.	7.1	419
264	Use of unpaid and paid home care services among people with HIV infection in the USA. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2001, 13, 99-121.	1.2	8
265	Effect of Insurance on Mortality in an HIV-Positive Population in Care. <i>Journal of the American Statistical Association</i> , 2001, 96, 883-894.	3.1	113
266	Re: Surveys Identify Barriers to Participation in Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2001, 93, 238-239.	6.3	3
267	Measuring the Incremental Cost of Clinical Cancer Research. <i>Journal of Clinical Oncology</i> , 2001, 19, 105-110.	1.6	27
268	Using Hospital Tumor Registries to Identify Research Subjects. <i>Health Services and Outcomes Research Methodology</i> , 2001, 2, 67-76.	1.8	1
269	The Impact of State Policy on the Costs of HIV Infection. <i>Medical Care Research and Review</i> , 2001, 58, 31-53.	2.1	25
270	Expenditures for the Care of HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2001, 344, 817-823.	27.0	274

#	ARTICLE	IF	CITATIONS
271	Methodological biases in estimating the burden of out-of-pocket expenses. Health Services Research, 2001, 35, 1357-65; discussion 1365-70.	2.0	29
272	Providing Managed Care Options for a Large Population: Evaluating the CHAMPUS Reform Initiative. Military Medicine, 2000, 165, 403-410.	0.8	3
273	Queuing for Surgery: Is the U.S. or Canada Worse Off?. Review of Economics and Statistics, 2000, 82, 297-308.	4.3	17
274	Improving the quality of care through routine teleradiology consultation. Academic Radiology, 2000, 7, 149-155.	2.5	20
275	Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Services Research, 2000, 35, 389-416.	2.0	162
276	Variations in the Care of HIV-Infected Adults in the United States. JAMA - Journal of the American Medical Association, 1999, 281, 2305.	7.4	669
277	Managed Care in Dental Markets: Is the Experience of Medicine Relevant?. Journal of Public Health Dentistry, 1999, 59, 24-32.	1.2	6
278	Variation in Inpatient Resource Use in the Treatment of HIV. Medical Care, 1999, 37, 220-227.	2.4	18
279	The Care of HIV-Infected Adults in the United States. New England Journal of Medicine, 1998, 339, 1897-1904.	27.0	503
280	Cost-Containment and Adverse Selection in Medicaid HMOs. Journal of the American Statistical Association, 1998, 93, 54-62.	3.1	32
281	Redistributional consequences of community rating. Health Services Research, 1997, 32, 71-86.	2.0	2
282	Managed Care as a Public Cost-Containment Mechanism. RAND Journal of Economics, 1995, 26, 277.	2.3	51
283	The effects of benefit design and managed care on health care costs. Journal of Health Economics, 1995, 14, 401-418.	2.7	16
284	Creating the Costliest Orphan: The Orphan Drug Act in the Development of Ceredase. International Journal of Technology Assessment in Health Care, 1992, 8, 583-597.	0.5	14
285	Food Prices and the Dynamics of Body Weight. , 0, , 65-90.		12
286	Understanding the Economic Consequences of Shifting Trends in Population Health. SSRN Electronic Journal, 0, , .	0.4	1
287	International Differences in Longevity and Health and Their Economic Consequences. SSRN Electronic Journal, 0, , .	0.4	1
288	Terminal Care and the Value of Life Near its End. SSRN Electronic Journal, 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
289	Moral Hazard and Adverse Selection in Private Health Insurance. SSRN Electronic Journal, 0, , .	0.4	0
290	The Future of the Elderly Population Health Status: Filling a Knowledge Gap. SSRN Electronic Journal, 0, , .	0.4	0
291	The Returns to Preventing Chronic Disease in Europe and the United States. Journal of Human Capital, 0, , 000-000.	1.3	0